CRISPR Gene Editing Newsletter
Issue #60October 26, 20267 studies

A CRISPR nickase shrank Huntington's repeats in mouse brains — and improved movement

Gene editing got a little more therapeutic this week — a CRISPR tool designed to nick, not cut, shrank the stuttering DNA repeats behind Huntington's disease in living mouse brains.

Elsewhere, a phage pulled off a molecular con job that has researchers rethinking how CRISPR defenses can be beaten.

🧠 A CRISPR Nickase Took a Bite Out of Huntington's — in Actual Neurons

  • Researchers used a Cas9 nickase — a gentler version that cuts only one DNA strand — to shrink the expanded CAG repeats behind Huntington's disease. It worked in patient-derived neurons and astrocytes, and in a living mouse model.
  • In the R6/1 mouse striatum, repeat contractions showed up in more than half of neurons after a single injection. The mice had fewer toxic protein clumps, a healthier gene expression profile, and measurably better movement in open-field tests.
  • The approach was allele-selective — meaning it targeted the disease copy — and no detectable off-target mutations were found. The behavioral improvements were larger than the contraction rates alone would predict, suggesting neighboring cells may also be responding.

Why it matters: More than 15 diseases share this same repeat-expansion problem. A tool that contracts the repeats without cutting both strands — and without off-target edits — changes the calculus on what's fixable.

🥇 Top 1% journal 🔗 Science translational medicine Journal Article 🗓️ Oct 22

Key Findings

🦠 A Phage RNA Fools Cas9 by Wearing Its Own Guide as a Disguise

  • Scientists identified a phage-encoded small RNA, rAcrIIA1, that mimics the full single-guide RNA Cas9 needs to function. It binds Cas9 nearly identically to the real guide, blocking the system from loading any actual guide RNA and shutting down DNA cutting.
  • Structural analysis of the Cas9-rAcrIIA1 complex confirmed the mimicry. Crucially, the RNA is also reprogrammable: swap in a variable guide sequence and it directs Cas9 to cut specific DNA targets with efficiency comparable to the standard guide.
💡 A phage RNA that blocks and redirects Cas9 is a new class of molecular tool.
🥇 Top 1% journal 🔗 Cell host & microbe Journal Article 🗓️ Oct 22

🧬 Human Argonaute 2 Repurposed as an RNA Editor — With Fewer Foreign-Protein Concerns

  • Researchers fused human Argonaute 2 (AGO2) to a deaminase enzyme to create ALTER, a C-to-U RNA editor built entirely from human proteins. In HEK293T cells, ALTER achieved on average 1.9-fold higher editing efficiency on messenger RNA targets compared to Cas13-based editors.
  • Because the scaffold is human, machine learning models predicted far fewer immunogenic peptides — a practical concern when moving toward therapeutic use. Off-target editing was similar to or lower than Cas13 comparators.
💡 Human-protein RNA editors may sidestep immune hurdles that foreign Cas systems face.
🏆 Top 0.1% journal 🔗 Nature biotechnology Journal Article 🗓️ Oct 20

🔬 A Phage Repair Kit Patches CRISPR Cuts — and Doubles as a Genome-Editing Tool

  • A two-protein system called Healer, encoded by phages, repairs DNA breaks caused by CRISPR rather than blocking the enzyme. One protein binds single-stranded DNA at the cut site; the other promotes homologous recombination to seal it.
  • When co-expressed with Cas9 or Cas12 in three bacterial species — E. coli, P. aeruginosa, and A. baumannii — the Healer system showed high phage genome-editing efficiency, suggesting a dual role as both a phage survival tool and a genome-engineering scaffold.
💡 Phages that fix CRISPR cuts could be co-opted to improve precision genome editing.
🥈 Top 2% journal 🔗 Nature communications Journal Article 🗓️ Oct 22

🌽 Chromosome-Scale Plant Editing Is Moving From Single Genes to Whole Regions

  • A review in Trends in Biotechnology maps how plant genome engineering has expanded from editing individual genes to rearranging megabase-scale chromosomal segments. Technologies now enable programmable deletions, insertions, inversions, and translocations across kilobase-to-megabase ranges.
  • AI integration is accelerating optimization of these large-fragment tools, and the authors argue the field is transitioning from genome editing to chromosome engineering — with direct implications for crop breeding and plant synthetic biology.
💡 Plant breeders can now think in chromosomes, not just genes.
🥉 Top 5% journal 🔗 Trends in biotechnology Review 🗓️ Oct 20

🩸 Blocking a Mitochondrial Protein Sensitizes a Leukemia to Its Own Drug

  • In acute myeloid leukemia driven by a common mutation called FLT3-ITD, cancer cells that resist the drug gilteritinib upregulate a mitochondrial protein called NDUFS2. A CRISPR screen pinpointed it; knocking it down impaired energy production and pushed resistant cells toward cell death.
  • Combining a pharmacologic mitochondrial inhibitor with gilteritinib reduced leukemia burden in a patient-derived mouse model. A short-term safety assessment in mice showed no overt toxicity, though the authors frame this as preliminary.
💡 Drug-resistant leukemia cells may carry a metabolic vulnerability worth targeting.
🥈 Top 2% journal 🔗 Leukemia Journal Article 🗓️ Oct 20

🖐️ A Single Gene Controls Touch, Temperature, Pain, and Itch in Sensory Neurons

  • Using a postnatal CRISPR-Cas9 screening platform delivered via AAV into mice, researchers knocked out 20 genes expressed in sensory neurons and tested behavior. One gene, Creld1, stood out: its loss caused profound deficits across touch, temperature, pain, and itch simultaneously.
  • Mechanistically, CRELD1 appears to regulate voltage-gated sodium channels that control how easily sensory neurons fire. Overexpressing Creld1 had the opposite effect, enhancing touch and thermal responses.
💡 One protein regulating four sensory modalities is an unusually broad single-gene finding.
🥇 Top 1% journal 🔗 Nature neuroscience Journal Article 🗓️ Oct 23

Implications

The Huntington's nickase result and the Creld1 sensory discovery both point to the same emerging reality: CRISPR is moving from proof-of-concept edits to measurable phenotypic rescue. The unresolved tension is whether non-cell-autonomous effects — neighbors responding to edited cells — can be predicted or controlled well enough to treat humans safely.

Studies in this issue

Primary sources used for this newsletter.

  1. From Changing Genes to Reshaping Chromosomes in Plants
    key findingTrends in biotechnology2026-10-20PMID 42901830
  2. A phage DUF669 protein helps fix DNA after cutting to resist host CRISPR defense
    key findingNature communications2026-10-22PMID 42907433
  3. A virus-made small RNA that mimics guide RNA to block CRISPR-Cas9
    key findingCell host & microbe2026-10-22PMID 42906550
  4. Designed human Argonaute 2 protein for precise RNA editing from C to U
    key findingNature biotechnology2026-10-20PMID 42902027